My­lan claims win in Lan­tus patent bat­tle, but le­gal war with Sanofi is far from over

Ear­li­er this week, the FDA took aim at es­ca­lat­ing in­sulin prices that have forced di­a­bet­ics to ra­tion out the drug as out-of-pock­et costs soar. Now, the US Patent and Trade­mark Of­fice has de­nied Sanofi’s claim on two patents for its top-sell­ing Lan­tus, in re­sponse to a pe­ti­tion from My­lan, al­though on­go­ing lit­i­ga­tion be­tween the two com­pa­nies in US courts could still sub­vert a po­ten­tial launch of the gener­ic drug­mak­er’s copy­cat ver­sion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.